Inclusion Criteria:

- High Risk Prostate Cancer as defined as ONE of the following:

1. Clinical T2b-T4

2. Gleason sum score 8-10

3. PSA more than 20 and Gleason sum score 7

4. In addition, clinical T2a patients are eligible if 5 or more biopsies contain
Gleason 4+3 cancer (minimum of 10 biopsies total required)

- No evidence of metastatic disease within 60 days of enrollment, confirmed by physical
examination, chest x-ray, bone scan, and computed tomography of the abdomen and
pelvis

- ECOG performance status of 0, 1 or 2

Exclusion Criteria:

- Concurrent or prior treatment with radiation, cytotoxic, biologic therapy for
prostate cancer; any major surgery within four weeks, prior hormonal therapy (except
finasteride for obstructive voiding symptoms)

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, anticipation of need for major surgical procedure during the course
of the study; Minor surgical procedures such as fine needle aspirations or core
biopsies within 7 days prior to Day 0

- Presence of central nervous system or brain metastases

- Blood pressure of >150/100 mmHg

- History of myocardial infarction within 6 months

- History of stroke within 6 months

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
bevacizumab cancer study